• KayeMeier
  • 20 February, 2017
  • The ISSCR has named Kaye Meier to be its new Director of Policy. Meier is responsible for directing, planning, and executing policy and advocacy efforts, enabling the society and its members to actively engage in shaping stem cell-related public policy around the world.
    Full story
  • 10 February, 2017
  • The ISSCR Board writes a letter to the stem cell community regarding travel to the ISSCR 2017 meeting, 14-17 June.
    Full story
  • 30 January, 2017
  • 1/30/2017 6:00:00 AM

    The ISSCR issued a statement opposing a U.S. executive order on immigration.
    Full story
  • ISSCR Comments on 21st Century Cures Act in U.S.

  • 9 December, 2016
  • The ISSCR supports the increase in biomedical research funding in the 21st Century Cures Act in the U.S. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story
  • ISSCR Comments on 21st Century Cures Act Under Consideration in U.S. Congress

  • 30 November, 2016
  • The ISSCR supports the increase in biomedical research funding in the current version of the 21st Century Cures Act. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story
  • ISSCR Opposes the REGROW Act

  • 15 September, 2016
  • The ISSCR opposes the REGROW Act, which would allow certain cell and tissue-based therapeutics to be marketed without first providing rigorous evidence of safety and efficacy. If passed, this legislation could negatively impact the development of stem cell therapies, the integrity of the emerging regenerative medicine market, and the health and safety of people using stem cell products approved under this Act.
    Full story
  • ISSCR Comments Before FDA Panel on Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

  • 13 September, 2016
  • The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.
    Full story
  • ISSCR Congratulates George Q. Daley on Being Named Dean of Harvard Medical School

  • 10 August, 2016
  • ISSCR Congratulates George Q. Daley, ISSCR past president, for being named dean of Harvard Medical School. August, 2016.
    Full story
  • ISSCR Favors NIH Proposal on Human-Animal Chimera Research

  • 8 August, 2016
  • The ISSCR is pleased that the U.S. National Institutes of Health (NIH) is considering an end to the moratorium on NIH funding of human-animal chimera research (NIH Notice, 8-4-16).
    Full story
  • ISSCR Submits Comments to NAS Regarding Human Gene Editing

  • 7 July, 2016
  • The ISSCR provided comments to the National Academy of Science/National Academy of Medicine Committee on Human Gene Editing regarding scientific, medical, and ethical considerations.
    Full story
  • ISSCR Releases Updated Guidelines for Stem Cell Research and Clinical Translation

  • 12 May, 2016
  • The ISSCR, the world’s largest professional organization of stem cell scientists, today released newly updated guidelines for stem cell research and the development of new clinical therapies. Guidance addresses key scientific, ethical, social, and policy challenges raised by new technologies and emerging areas of stem cell discovery and application.
    Full story
  • ISSCR Endorses Fetal Tissue Research as Essential

  • 26 February, 2016
  • The International Society for Stem Cell Research (ISSCR) is the world’s leading professional organization of stem cell scientists, representing more than 4,000 members in 45 U.S. states and 65 countries around the world. The ISSCR is opposed to recent efforts to inappropriately limit or prohibit biomedical research using fetal tissue. These proposals, if enacted, would obstruct critical biomedical research and inhibit efforts to improve human health. If enacted in the past, such limits would have delayed or prevented the development of therapies that have saved millions of lives.
    Full story
  • Remembering Dr. John McNeish

  • 3 December, 2015
  • The ISSCR, together with the stem cell research community, recognizes with sadness the recent death of our colleague, Dr. John D. McNeish.
    Full story
  • The ISSCR Remembers Dr. John McNeish

  • 3 December, 2015
  • 12/3/2015 6:00:00 AM

    The ISSCR Remembers Dr. John McNeish, a leader in stem cell research and regenerative medicine, and a long-time ISSCR member.
    Full story
  • The ISSCR Announces Melbourne as Site of 2018 Annual Meeting

  • 12 November, 2015
  • The ISSCR is announcing that Melbourne, Australia has been chosen as the location of its 2018 annual meeting.
    Full story
  • International Society for Stem Cell Research Announces New Policy Hire

  • 1 October, 2015
  • The ISSCR has hired a director for its policy office. The individual is responsible for directing, planning and executing the society’s policy initiatives to impact standards, policy and regulation pertaining to stem cell research at the state and federal levels as well as internationally.
    Full story
  • The ISSCR has Responded to the Publication of Gene Editing Research in Human Embryos

  • 23 April, 2015
  • In response to an article published by Chinese scientists describing research that used gene editing technologies in human embryos, the International Society for Stem Cell Research (ISSCR) has again called for a moratorium on attempts at human clinical germline genome editing while extensive scientific analysis of the potential risks is conducted, along with broad public discussion of the societal and ethical implications.
    Full story
  • The ISSCR Statement on Human Germline Genome Modification

  • 19 March, 2015
  • The International Society for Stem Cell Research calls for a moratorium on attempts at clinical application of nuclear genome editing of the human germ line to enable more extensive scientific analysis of the potential risks of genome editing and broader public discussion of the societal and ethical implications.
    Full story
  • The ISSCR Welcomes the Response by the EU Commission to Concerns around hESC Research Funding

  • 30 May, 2014
  • The ISSCR welcomes the recent EU Commission’s response to concerns about how funding from the Horizon 2020 EU Research and Innovation program is to be used for human embryonic stem cell research. The ISSCR advocates that all forms of stem cell research are crucial for the advancement of our understanding of human health and disease and for the development of novel treatments.
    Full story
    View All ISSCR News